Literature DB >> 8524490

Cellular mechanism of resistance to erythropoietin.

N Casadevall1.   

Abstract

Erythropoiesis is controlled by different regulators. Interleukin 3, granulocyte-macrophage colony-stimulating factor and stem cell factor play regulatory functions in the early steps of erythropoiesis. Erythropoietin (Epo) is the main factor which acts positively on the last steps of the production of erythrocytes in mammals. Epo is specific for the erythroid progenitor cells and has only little effect on other cells. The target cells for Epo are the erythroid progenitors (BFUe and CFUe). Epo acts on these progenitors through surface receptors specific for Epo. Epo induces the proliferation and differentiation of erythroid progenitors leading finally to reticulocytes. During this process, certain conditions are required to permit this differentiation: progenitors must be present in sufficient numbers, the bone marrow environment must be normal, and nutrients such as folic acid, vitamin B12 and particularly iron must be available. Elemental iron is an absolute requirement for adequate haemoglobin formation. Indeed, in a normal adult, without any stimulation, the bone marrow synthesizes 4 x 10(14) molecules of haemoglobin per second, each molecule containing four atoms of iron, which roughly corresponds to 20 mg iron. On the other hand, erythropoiesis is negatively regulated by several cytokines. These are macrophage-derived cytokines, including tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), interleukin-6 (IL-6) and transforming growth factor-beta (TGF-beta). All these factors are elevated in the inflammatory state and are implicated in the pathogenesis of anaemia of chronic disease. TNF-alpha has an inhibitory effect on erythroid progenitors either directly or mediated by interferon-beta (INF-beta). IL-1 inhibits erythropoiesis in vivo in mice and in vitro in humans.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8524490     DOI: 10.1093/ndt/10.supp6.27

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  9 in total

Review 1.  Statins, inflammation and kidney disease.

Authors:  Vera Krane; Christoph Wanner
Journal:  Nat Rev Nephrol       Date:  2011-05-31       Impact factor: 28.314

2.  Iron and CF-related anemia: expanding clinical and biochemical relationships.

Authors:  A H Gifford; S D Miller; B P Jackson; T H Hampton; G A O'Toole; B A Stanton; H W Parker
Journal:  Pediatr Pulmonol       Date:  2010-10-20

3.  Receptor-based dosing optimization of erythropoietin in juvenile sheep after phlebotomy.

Authors:  Matthew Rosebraugh; John A Widness; Peter Veng-Pedersen
Journal:  Drug Metab Dispos       Date:  2011-04-01       Impact factor: 3.922

Review 4.  Erythropoietin-Stimulating Agent Hyporesponsiveness in Patients Living with Chronic Kidney Disease.

Authors:  Henry H L Wu; Rajkumar Chinnadurai
Journal:  Kidney Dis (Basel)       Date:  2022-01-14

5.  Interleukin-6 producing pheochromocytoma presenting with acute inflammatory syndrome.

Authors:  M Minetto; A Dovio; M Ventura; S Cappia; F Daffara; M Terzolo; A Angeli
Journal:  J Endocrinol Invest       Date:  2003-05       Impact factor: 4.256

6.  Gut Microbiota Correlates With Clinical Responsiveness to Erythropoietin in Hemodialysis Patients With Anemia.

Authors:  Yifan Zhu; Yuyan Tang; Haidong He; Ping Hu; Weiqian Sun; Meiping Jin; Lishun Wang; Xudong Xu
Journal:  Front Cell Infect Microbiol       Date:  2022-07-22       Impact factor: 6.073

7.  Oral Administration of Ren-Shen-Yang-Rong-Tang 'Ninjin'yoeito' Protects Against Hematotoxicity and Induces Immature Erythroid Progenitor Cells in 5-Fluorouracil-induced Anemia.

Authors:  Fumihide Takano; Yasuyuki Ohta; Tomoaki Tanaka; Kenroh Sasaki; Kyoko Kobayashi; Tomoya Takahashi; Nobuo Yahagi; Fumihiko Yoshizaki; Shinji Fushiya; Tomihisa Ohta
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-27       Impact factor: 2.629

8.  Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics.

Authors:  David T Gilbertson; Yi Peng; Thomas J Arneson; Stephan Dunning; Allan J Collins
Journal:  BMC Nephrol       Date:  2013-02-20       Impact factor: 2.388

9.  The relationship between Type D personality, affective symptoms and hemoglobin levels in chronic heart failure.

Authors:  Nina Kupper; Aline J Pelle; Balázs M Szabó; Johan Denollet
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.